Growth Factor Clinical Trials

1 recruiting

Growth Factor Trials at a Glance

15 actively recruiting trials for growth factor are listed on ClinicalTrialsFinder across 6 cities in 18 countries. The largest study group is Phase 1 with 6 trials, with the heaviest enrollment activity in Houston, Los Angeles, and Nashville. Lead sponsors running growth factor studies include Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc., Genmab, and EpiBiologics.

Browse growth factor trials by phase

Treatments under study

About Growth Factor Clinical Trials

Looking for clinical trials for Growth Factor? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Growth Factor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Growth Factor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Phase 1

Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

Phase 1Clear Cell CarcinomaGrowth Factor
M.D. Anderson Cancer Center30 enrolled1 locationNCT07072234
Recruiting
Phase 1Phase 2

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Pancreatic Adenocarcinoma+2 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 2

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.220 enrolled80 locationsNCT05967689
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Endometrial CancerPrimary Peritoneal CarcinomaNon-small Cell Lung Cancer+6 more
Genmab764 enrolled66 locationsNCT05579366
Recruiting
Phase 1Phase 2

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Breast CancerBreast Cancer MetastaticOvarian Cancer+6 more
Incyclix Bio150 enrolled18 locationsNCT05735080
Recruiting
Phase 1

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

Epidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Gene MutationEpidermal Growth Factor+1 more
EpiBiologics110 enrolled5 locationsNCT07462377
Recruiting
Phase 2

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Breast CancerHER2-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast
University of Chicago74 enrolled4 locationsNCT06348134
Recruiting
Not Applicable

Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant

Diabetes MellitusOxidative StressHyperglycaemia (Diabetic)+4 more
Vastra Gotaland Region150 enrolled2 locationsNCT06984822
Recruiting
Phase 1Phase 2

Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells

Glioblastoma MultiformeGlycolytic IndexEpidermal Growth Factor Receptor
Jonsson Comprehensive Cancer Center50 enrolled1 locationNCT06059690
Recruiting
Not Applicable

Concerned Growth Factor VS Miniral Trioide Aggregate in Treatment of Mature Permanent Teeth of Children With Symptomatic Irreversible Pulpitis.

Concerned Growth Factor Versus Miniral Trioide Aggregate in Management of Mature Permanent Molar With Irreversible Pulpitis
Minia University200 enrolled1 locationNCT07138287
Recruiting
Not Applicable

Intracameral Versus Intravitreal Bevacizumab Injection in NVG: RCT

Glaucoma, NeovascularVascular Endothelial Growth Factor Overexpression
Prince of Songkla University40 enrolled1 locationNCT03648814
Recruiting

FGF23 and Cardiovascular Damage in Anemia With an Without Chronic Kidney Disease.

AnemiaCKDFibroblast Growth Factor 23
Maimónides Biomedical Research Institute of Córdoba401 enrolled1 locationNCT05356325
Recruiting
Early Phase 1

Gene Expression Changes In Young and Geriatric Skin

AgingUVB Phototherapy BurnInsulin-like Growth Factor 1
Wright State University24 enrolled1 locationNCT03932162
Recruiting

LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Universitaire Ziekenhuizen KU Leuven39 enrolled1 locationNCT04216121
Recruiting
Not Applicable

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Kunming Medical University30 enrolled1 locationNCT06102928